Patients with systemic lupus erythematosus who receive belimumab monotherapy show comparable remission rates and disease control to those who receive combination therapy with immunosuppressants.
A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in ...
SIGLEC‑1 expression correlates with disease activity in patients with lupus erythematosus during type I interferon blockade ...
The U.S. Food and Drug Administration has cleared (when a clinical study sponsor receives approval to administer an investigational drug or biological product to humans) an application for a new ...
Discrimination was linked to increased systemic lupus erythematosus symptom burden, mediated by symptoms of depression and ...
Biogen (NASDAQ:BIIB) outlined its immunology and neurology development priorities during a virtual symposium hosted by Piper ...
Findings from the APPEAL study, published in ACR Open Rheumatology, reveal that falls are a frequent but underrecognized ...
The FDA has granted Breakthrough Therapy designation for litifilimab for the treatment of cutaneous lupus erythematosus, a chronic autoimmune skin disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results